GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » Debt-to-Revenue

Redhill Biopharma (Redhill Biopharma) Debt-to-Revenue : 0.32 (As of Jun. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Redhill Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $1.29 Mil. Redhill Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.99 Mil. Redhill Biopharma's annualized Revenue for the quarter that ended in Jun. 2023 was $7.18 Mil. Redhill Biopharma's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 was 0.32.


Redhill Biopharma Debt-to-Revenue Historical Data

The historical data trend for Redhill Biopharma's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Debt-to-Revenue Chart

Redhill Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.61 1.35 1.02 1.99 0.18

Redhill Biopharma Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.72 2.40 0.49 0.32 N/A

Competitive Comparison of Redhill Biopharma's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redhill Biopharma's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's Debt-to-Revenue falls into.



Redhill Biopharma Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Redhill Biopharma's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.718 + 0.455) / 6.53
=0.18

Redhill Biopharma's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.29 + 0.994) / 7.184
=0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jun. 2023) Revenue data.


Redhill Biopharma Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Redhill Biopharma (Redhill Biopharma) Business Description

Traded in Other Exchanges
Address
21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.